Neogen Chemicals Limited makes a corporate announcement

Neogen Chemicals Limited’s consolidated net debt-to-equity ratio stood at 1.62x at the end of Q4 FY26 `<sup>[1]</sup>`. For Q1 FY27 (ended June 30, 2026), the consolidated total debt-to-equity ratio was reported at 1.40x `<sup>[2]</sup>` (alongside a standalone ratio of 0.68x `<sup>[3]</sup>`), driven by total consolidated debt of INR 1,329.9 crore `<sup>[4]</sup>` and net debt of INR 1,325 crore `<sup>[5]</sup>`.

QIP Proceeds Utilization and Deleveraging Intent

• Primary Deleveraging Focus: The Board approved raising up to INR 600 crore via a Qualified Institutional Placement (QIP) `<sup>[6]</sup>`. Management intends to direct these proceeds primarily toward debt reduction and balance sheet strengthening `<sup>[7]</sup>`.
• Mitigating Finance Costs: Elevated leverage—compounded by debt drawdowns for the Dahej plant rebuild and subsidiary expansion—pushed Q1 FY27 finance costs up by 64% year-on-year to INR 20.8 crore `<sup>[8]</sup>`, `<sup>[7]</sup>`. Deploying QIP proceeds toward debt repayment is targeted at easing this interest burden and maintaining peak net debt below INR 1,500 crore `<sup>[7]</sup>`.
• Neogen Ionics Subsidiary Funding: The ongoing capital expenditure requirements for the Neogen Ionics subsidiary (part of an expanded total project cost of INR 1,795 crore) have been funded through a combination of existing term debt, a INR 161 crore promoter equity infusion, a USD 20 million equity contribution from JV partner Morita, and insurance claim realizations (cumulative recoveries of INR 164 crore with net receivables of INR 186 crore) rather than direct primary allocation from the proposed QIP `<sup>[9]</sup>`, `<sup>[10]</sup>`, `<sup>[11]</sup>`, `<sup>[12]</sup>`.

Executive Summary

• Board Resolution Scope: On July 24, 2026, the Board of Directors granted in-principle approval to raise capital up to Rs 600 Crores through equity or equity-linked securities, including a Qualified Institutions Placement (QIP) ^[13]. While the initial board outcome filing provides an enabling mandate without an itemized breakdown ^[13], management disclosures indicate the capital is earmarked primarily to cover the balance project capital expenditure of Rs 600–700 Crores required in FY27 ^[14] for the battery materials expansion, along with working capital and general corporate purposes.
• Capital Allocation & Expansion Alignment: The proposed Rs 600 Crore infusion directly bridges the funding gap for Neogen Ionics' greenfield battery materials program, which has a total revised capital cost of Rs 1,795 Crores ^[15]. With Rs 1,298 Crores deployed through Q1 FY27 ^[15], the remaining capex of Rs 497 Crores (derived from Rs 1,795 Crores minus Rs 1,298 Crores ^[15]) aligns with the completion of Electrolyte facilities in H1 FY27 and Electrolyte Salts facilities in H2 FY27 ^[15].
• Specialty Chemical Segment: The core specialty chemicals business requires minimal incremental capital, as the post-fire replacement plant at Dahej reached completion around mid-2026 ^[16], funded largely via insurance claim realizations totaling Rs 164 Crores ^[13]. Near-term base-business expansion relies on low-capex debottlenecking (Rs 10–15 Crores for Organolithium in H2 FY27) ^[8].

---

Board Resolution & Stated End-Use of Proceeds

The Board approved an enabling resolution on July 24, 2026, to raise up to Rs 600 Crores ^[13]. The primary features of this capital action and its end-use profile include:

• Enabling Mandate: In-principle approval to issue financial instruments—including QIPs, convertible debentures, or equity shares—up to an aggregate limit of Rs 600 Crores ^[13].
• End-Use Targeted Allocation: Management commentary confirms that the balance capex required to complete all ongoing project phases in FY27 stands at Rs 600–700 Crores ^[14]. The equity raise ensures project completion without over-leveraging the balance sheet.
• Preceding Allotment Context: This follows an earlier preferential issue of Rs 161 Crores approved on March 7, 2026, and fully deployed by June 30, 2026 ^[17]. That issue was explicitly itemized and deployed as Rs 100 Crores for capital expenditure at Neogen Ionics' Pakhajan project, Rs 21 Crores for cash credit facility debt adjustment, and Rs 40 Crores for general corporate purposes ^[17].

---

Alignment with Segment Capacity Expansion Timelines

1. Electrolyte & Battery Chemicals Segment (Neogen Ionics Limited)

The capital allocation aligns directly with the revised timeline and capital outlay for Neogen Ionics' flagship battery materials projects ^[15].

• Notes: † Implied balance capex derived by subtracting Rs 1,298 Crores spent from Rs 1,795 Crores total budget ^[15].*
• Electrolyte Timelines: Commercial production ramp-up is scheduled for H1 FY27 ^[15]. Equipment from Mitsubishi Engineering Corporation has been assembled at site, moving the plant into active trial runs and customer validation with domestic cell manufacturers ^[15].
• Electrolyte Salts Timelines: Commercial scaling is scheduled for H2 FY27 ^[15]. Provisional approvals have been secured from four major international customers, and final site audits for three US-based electrolyte makers were completed ^[15].
• Strategic Fit: The Rs 600 Crore fundraise provides the remaining liquidity required to complete civil, fabrication, and equipment procurement without delaying mechanical completion schedules ^[15], ^[14].

2. Specialty Chemicals & Base Business Segment

• Dahej Replacement Plant Rebuild: Following the March 2025 fire incident, rebuilding of the core Dahej unit reached operational readiness around mid-2026 / Q1 FY27 ^[19], ^[16]. Capital for this reconstruction was supplied via internal accruals, short-term debt, and insurance recoveries (Rs 164 Crores recovered to date against net claim receivables of Rs 185.85 Crores) ^[13].
• Standalone Capacity & Guidance: Standalone operations are resuming normalized utilization, supported by MPP-5 reaching full production ^[16]. Standalone revenue guidance for FY27 is maintained at Rs 875–950 Crores ^[16].
• Incremental Expansion: Management envisions minimal standalone capital requirements for the specialty chemical segment, proposing a low-capex addition of Rs 10–15 Crores in H2 FY27 to expand Organolithium capacity following record Q1 FY27 sales ^[8].

---

Analytical Implications & Execution Risks

• Capital Structure & Debt Protection: Raising up to Rs 600 Crores via equity/QIP prevents further balance sheet strain during a high-capex cycle ^[13]. Consolidated interest expenses had increased significantly in prior quarters due to bridge borrowings for plant rebuilding ^[20].
• Off-Take Risk Transfer: The timely deployment of capital directly impacts Neogen's ability to capitalize on domestic Advanced Chemistry Cell (ACC) PLI manufacturing timelines ^[19]. Because trial runs are already underway for Electrolytes ^[15], any execution delay in deploying the final tranche of capex would risk customer qualification lead times for global non-FEOC supply chains ^[19], ^[21].
• Disclosure Gap: The precise final mix between QIP equity dilution and long-term project debt within the overall Rs 600 Crore limit remains subject to final board placement terms and execution timing ^[13].*

A ₹600 crore Qualified Institutional Placement (QIP) by Neogen Chemicals implies an estimated equity dilution of 10.6% to 10.8%, evaluated against a current market capitalization of approximately Rs 5,543 Crores to Rs 5,673 Crores ^[22] (derived from a stock price of ~Rs 2,024 and a post-preferential share base of 2.74 crore shares ^[23]). Assuming the QIP is priced near prevailing market levels, it would add roughly 29.6 million shares to the existing 2.74 crore equity base.

Historical Equity Issuance Frequency (FY24–FY26)

Over the last three fiscal years, Neogen has relied on periodic, opportunistic preferential allotments rather than broad public QIPs to fund its aggressive expansion:

• FY24 (November 2023): Raised Rs 253 Crores via a preferential allotment of 1,442,358 equity shares at Rs 1,754.07 per share to institutional investors (including SBI Mutual Fund, Quant Mutual Fund, and Tata India Mutual Fund) ^[24].
• FY25: Zero equity issuance; share capital remained unchanged at 2.64 crore shares ^[25].
• FY26 / Early FY27 (April 2026): Raised Rs 161 Crores via a preferential allotment of 1,000,000 equity shares at Rs 1,610 per share to promoter group entity Cadamba Solutions Private Limited ^[13].
• Comparison: The proposed ₹600 crore QIP is more than double the size of the FY24 institutional raise and nearly four times the size of the April 2026 promoter raise. Unlike past preferential allotments targeted at specific strategic investors, a QIP represents the company's first large-scale public institutional equity dilution of this magnitude.

Evolution of the Debt-Funding Mix (FY24–FY26)

Neogen’s funding mix has shifted dramatically over the past three fiscal years, moving from moderate leverage to heavy debt reliance to finance its greenfield battery materials expansion (Pakhajan and Dahej projects, carrying a total projected cost of Rs 1,795 Crores ^[26]):

• FY24: Consolidated gross debt stood at Rs 393.53 Crores (net debt of Rs 381.30 Crores), with a conservative debt-to-equity ratio of 0.52x ^[27].
• FY25: Consolidated gross debt increased to Rs 566.04 Crores (net debt of Rs 561.08 Crores), with debt-to-equity inching up to 0.72x ^[27].
• FY26: Consolidated gross debt surged to Rs 1,329.9 Crores (net debt of Rs 1,325.0 Crores), driving the debt-to-equity ratio sharply higher to 1.63x ^[27]. This debt expansion included a private placement of Rs 200 crore in Non-Convertible Debentures (NCDs) at a 10.50% coupon in August 2025 ^[28] and large-scale term loan financing (such as an SBI facility of ~Rs 894 crore for subsidiary Neogen Ionics) ^[29].

Strategic Implications

The pivot toward a ₹600 crore equity QIP marks a necessary de-leveraging inflection point. With net debt scaling to Rs 1,325 Crores against a net worth of Rs 816 Crores by March 2026—and credit rating pressures reflecting elevated leverage ^[22]—management intends to deploy QIP proceeds primarily toward debt reduction ^[7]. Full deployment toward debt retirement is projected to lower annual finance costs by ₹40–50 crores ^[7], mitigating the margin drag from elevated interest expenses while preserving balance-sheet capacity to complete the Dahej and Pakhajan battery material commissioning milestones through FY27.